Virios Therapeutics Files Administrative 8-K; No New Material Events
Ticker: DWTX · Form: 8-K · Filed: Jan 3, 2024 · CIK: 1818844
| Field | Detail |
|---|---|
| Company | Virios Therapeutics, INC. (DWTX) |
| Form Type | 8-K |
| Filed Date | Jan 3, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: administrative, corporate-governance, regulation-fd
TL;DR
**Virios Therapeutics filed a routine 8-K, mostly administrative, no big news for VIRI.**
AI Summary
Virios Therapeutics, Inc. filed an 8-K on January 3, 2024, primarily to disclose general corporate information and confirm its status as a publicly traded company on the Nasdaq Capital Market under the ticker VIRI. This filing, categorized under Regulation FD Disclosure and Financial Statements and Exhibits, doesn't announce any new material events like acquisitions or earnings, but rather updates administrative details. For investors, this filing is largely administrative and doesn't present new information that would immediately impact the stock price, but it confirms the company's ongoing compliance and operational status.
Why It Matters
This filing is largely administrative, confirming Virios Therapeutics' corporate details and public listing. It doesn't contain new financial or operational news that would directly affect the stock price.
Risk Assessment
Risk Level: low — This 8-K filing is administrative and does not disclose any new risks or material events that would impact the company's risk profile.
Analyst Insight
Given this is an administrative filing with no new material information, a smart investor would likely maintain their current position or continue with their existing research without immediate action based solely on this 8-K.
Key Numbers
- $0.0001 — par value per share (the par value of Virios Therapeutics' Common Stock)
Key Players & Entities
- Virios Therapeutics, Inc. (company) — the registrant filing the 8-K
- Nasdaq Capital Market (company) — the exchange where Virios Therapeutics' common stock is registered
- VIRI (company) — the trading symbol for Virios Therapeutics' common stock
- January 3, 2024 (date) — the date of the earliest event reported and the filing date
- 001-39811 (dollar_amount) — the Commission File Number for Virios Therapeutics
FAQ
What is the primary purpose of this 8-K filing by Virios Therapeutics, Inc.?
The primary purpose of this 8-K filing, dated January 3, 2024, is to disclose general corporate information under Regulation FD Disclosure and Financial Statements and Exhibits, confirming administrative details rather than announcing new material events.
On which stock exchange is Virios Therapeutics, Inc. common stock traded, and what is its trading symbol?
Virios Therapeutics, Inc. common stock is registered on the Nasdaq Capital Market under the trading symbol VIRI.
What is the par value of Virios Therapeutics, Inc.'s Common Stock as stated in the filing?
The par value of Virios Therapeutics, Inc.'s Common Stock is stated as $0.0001.
What is the business address and phone number of Virios Therapeutics, Inc.?
The business address for Virios Therapeutics, Inc. is 44 Milton Avenue, Alpharetta, GA 30009, and its telephone number is (866) 620-8655.
What was the earliest event reported date for this 8-K filing?
The date of the earliest event reported for this 8-K filing was January 3, 2024.
Filing Stats: 523 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2024-01-03 07:05:33
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 VIRI Nasdaq Capital Market Check t
Filing Documents
- tmb-20240103x8k.htm (8-K) — 41KB
- tmb-20240103xex99d1.htm (EX-99.1) — 21KB
- tmb-20240103xex99d1001.jpg (GRAPHIC) — 10KB
- 0001558370-24-000019.txt ( ) — 200KB
- tmb-20240103.xsd (EX-101.SCH) — 3KB
- tmb-20240103_lab.xml (EX-101.LAB) — 16KB
- tmb-20240103_pre.xml (EX-101.PRE) — 10KB
- tmb-20240103x8k_htm.xml (XML) — 5KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On January 3, 2024, Virios Therapeutics Inc. (the "Company") issued a letter to shareholders. A copy of the letter is included as Exhibit 99.1 to this Current Report on Form 8-K and is hereby incorporated by reference into this Item 7.01. In addition, a copy of this letter will be posted to the Company's website. The information in this Item 7.01, including the attached exhibits, is furnished solely pursuant to Item 7.01 of Form 8-K. Consequently, such information is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that section. Further, the information in this Item 7.01, including the exhibits, shall not be deemed to be incorporated by reference into the filings of the registrant under the Securities Act of 1933.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits . Exhibit Number Description 99.1 Shareholder Letter, dated January 3, 2024 (furnished herewith). 104 Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101) 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VIRIOS THERAPEUTICS, INC. By: /s/ Angela Walsh Name: Angela Walsh Title: Senior Vice President of Finance and Corporate Secretary and Treasurer January 3, 2024 3